In July 2020, Fostemsavir (RUKOBIA) received approval by the FDA as a new type of antiretroviral medication for adults living with HIV/AIDS.


It is indicated for the treatment of HIV-1 in heavily treatment-experienced patients with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen caused by resistance, intolerance, or safety considerations. Fostemsavir is an HIV-1 glycoprotein 120-directed attachment inhibitor. By blocking this highly conserved area of the virus, it prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell. Such a path of action is first for HIV drugs.


Fostemsavir contains 1H-pyrrolo[2,3-c]pyridine moiety in its backbone. We have made a set of Building Blocks, which contain such part – the perfect start for your research!